Forget Fibrates for Cardiovascular Risk Reduction: Commentary on the Failure and Implications of the PROMINENT Trial

Article Type
Changed
Thu, 06/08/2023 - 09:18

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc.
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc.
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc.

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored Supplement
Gate On Date
Wed, 04/12/2023 - 09:30
Un-Gate On Date
Wed, 04/12/2023 - 09:30
Use ProPublica
CFC Schedule Remove Status
Wed, 04/12/2023 - 09:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
377933.2